Evidence map›Paper›PMID 29780126›Full record

ArticleInternal medicine (Tokyo, Japan)2018

Intractable Hemophagocytic Syndrome Associated with Systemic Lupus Erythematosus Resistant to Corticosteroids and Intravenous Cyclophosphamide That Was Successfully Treated with Cyclosporine A.

Hirofumi Toko, Hiroto Tsuboi, Naoto Umeda, Fumika Honda, Ayako Ohyama, Hidenori Takahashi, Saori Abe, Masahiro Yokosawa, Hiromitsu Asashima, Shinya Hagiwara and 4 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Hirofumi TokoDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Hiroto TsuboiDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Naoto UmedaDepartment of Rheumatology, Tsuchiura Kyodo General Hospital, Japan.
Fumika HondaDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Ayako OhyamaDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Hidenori TakahashiDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Saori AbeDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Masahiro YokosawaDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Hiromitsu AsashimaDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Shinya HagiwaraDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Tomoya HirotaDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Yuya KondoDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Isao MatsumotoDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Takayuki SumidaDepartment of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
University of Tsukuba · JPTsuchiura Kyodo General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophagocytic syndrome (HPS) associated with systemic lupus erythematosus (SLE), dubbed acute lupus hemophagocytic syndrome (ALHS), is an intractable complication of SLE. A 24-year-old man who had been diagnosed with SLE three months previously, presented with fever, rash, hallucination, and pancytopenia accompanied with hyperferritinemia and bone marrow hemophagocytosis. He was diagnosed with ALHS and neuropsychiatric (NP)-SLE. Although 4 courses of methylprednisolone pulse therapy and 1 course of intravenous cyclophosphamide (IVCY) improved his NP-SLE, his ALHS did not respond. However, the addition of cyclosporine A (CsA) led to a rapid remission from ALHS. This suggests the usefulness of CsA in the treatment of intractable, corticosteroid- and IVCY-resistant ALHS.

Indexed as

Administration, IntravenousAdrenal Cortex HormonesCyclophosphamideCyclosporineDermatologic AgentsHumansImmunosuppressive AgentsLupus Vasculitis, Central Nervous SystemLymphohistiocytosis, HemophagocyticMaleMethylprednisoloneYoung AdultAdrenal Cortex HormonesCyclophosphamideCyclosporineDermatologic AgentsImmunosuppressive AgentsMethylprednisoloneacute lupus hemophagocytic syndromecyclophosphamidecyclosporine Ahemophagocytic syndromesystemic lupus erythematosus

Identifiers

PMID29780126
PMCPMC6191589
OpenAlexW2804554339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.